Communicable disease threats report, 16-22 February 2020, week 8
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 16-22 February 2020 and includes updates on chikungunya, dengue, Ebola virus disease, COVID-19, polio, seasonal influenza and polio.
Seminar about the coronavirus
How is the coronavirus outbreak affecting Europe and Sweden and which counter measures are being taken? ECDC’s Director Andrea Ammon will explain the current rapidly evolving situation and what is being done at the European level. DG Johan Carlson from Folkhälsomyndigheten will explain what is the situation in Sweden.
Interim guidance for environmental cleaning in non-healthcare facilities exposed to SARS-CoV-2
This document aims to provide guidance about the environmental cleaning in non-healthcare facilities (e.g. rooms, public offices, transports, schools, etc.) where confirmed COVID-19 cases have been before being admitted to hospital. This guidance is based on the current knowledge about SARS-CoV-2 and evidence originating from studies on other coronaviruses.
Are European laboratories ready to detect COVID-19?
A first assessment looking at the preparedness of EU/EEA laboratories to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) demonstrates a fast implementation of molecular diagnostics by the European specialised laboratory networks. It also shows a good geographical coverage for testing.
Communicable disease threats report, 9-15 February 2020, week 7
This issue of the CDTR (Communicable Disease Threats Report) covers the period from 9-15 February 2020 and includes updates on COVID-19, Ebola virus disease, influenza and dengue fever.
Risk assessment: Outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): increased transmission beyond China – fourth update
On 31 December 2019, a cluster of pneumonia cases of unknown aetiology was reported in Wuhan, Hubei Province, China. On 9 January 2020, China CDC reported a novel coronavirus as the causative agent of this outbreak, which is phylogenetically in the SARS-CoV clade. The novel coronavirus has thus been named ‘severe acute respiratory syndrome coronavirus 2’ (SARS-CoV-2), while coronavirus disease associated with it is now referred to as COVID-19.
Guidelines for the use of non-pharmaceutical measures to delay and mitigate the impact of 2019-nCoV
This document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some of the measures proposed refer specifically to certain phases of the epidemic (containment or mitigation phases), and can be adapted depending on the assessed severity/impact of the infection. Other measures are valid for all phases of an epidemic.
Communicable Disease Threats Report, 2-8 February 2020, week 6
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 2-8 February 2020 and includes updates on Ebola virus disease, 2019-nCoV, polio, seasonal influenza and MERS.
- Democratic Republic of the Congo
- Ebola haemorrhagic fever
- Ebola outbreak - North Kivu, Ituri, DRC
- Influenza in humans, seasonal
- Middle East
- Middle East respiratory syndrome coronavirus
- Public health threat
- Saudi Arabia
- Travellers' health
- United Kingdom
Personal protective equipment (PPE) needs in healthcare settings for the care of patients with suspected or confirmed novel coronavirus (2019-nCoV)
The aim of this document is to support public health preparedness planning with regard to personal protective equipment (PPE) needs in healthcare settings where patients suspected or confirmed to have been infected with the novel coronavirus 2019-nCoV are being treated.